Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Proteomics01:33

Proteomics

7.4K
A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
7.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spatial distribution of the proteome in the human body and in cancers.

Nature·2026
Same author

DDA-BERT: end-to-end training for data-dependent acquisition mass spectrometry-based proteomics.

Nature communications·2026
Same author

A targeted proteomics assay for the preoperative diagnosis of thyroid nodules.

Cell reports. Medicine·2026
Same author

Discovery, α-Glucosidase Inhibitory Activity, and Structural Optimization of the Alkaloids from <i>Vanderbylia robiniophila</i> SY636.

Journal of natural products·2026
Same author

ZFHX3 is integral to androgen/AR signaling involving protein association with AR in prostate cancer cells.

Scientific reports·2025
Same author

The pan-cancer proteome atlas, a mass spectrometry-based landscape for discovering tumor biology, biomarkers, and therapeutic targets.

Cancer cell·2025
Same journal

Proteomic and glycosylation biomarkers in rheumatoid arthritis: advancing early diagnosis and precision therapy.

Clinical proteomics·2026
Same journal

Inverse co-variation of circulating PIWIL2 and PIWIL4 in gastric adenocarcinoma: an exploratory ELISA-based study.

Clinical proteomics·2026
Same journal

Comprehensive biochemical insights into derivatives of PSA and glycosylation-specific changes in PSA: role in diagnosis and management of prostate cancer.

Clinical proteomics·2026
Same journal

Proteomic analysis of malignant ascites and its impact on ovarian cancer spheroids.

Clinical proteomics·2026
Same journal

Repurposing the liquid-based Pap test for the detection of ovarian cancer protein biomarkers.

Clinical proteomics·2026
Same journal

Pairing of high-mannose glycans in human IgE-Fc: implications for secretion and stability.

Clinical proteomics·2026
See all related articles

Related Experiment Video

Updated: Jul 11, 2025

Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging
08:40

Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging

Published on: April 8, 2016

12.9K

A pathway activity-based proteomic classifier stratifies prostate tumors into two subtypes.

Rui Sun1,2,3, Lingling Tan4, Xuan Ding5,6,7

  • 1Westlake Center for Intelligent Proteomics, Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, Zhejiang, China. sunrui@westlake.edu.cn.

Clinical Proteomics
|November 10, 2023
PubMed
Summary
This summary is machine-generated.

Researchers identified two prostate cancer (PCa) subtypes, PPS1 and PPS2, based on protein activity. PPS2, linked to suppressed immunity and cell proliferation, correlates with poorer survival outcomes in PCa patients.

Keywords:
BCR-free survivalProstate cancerProteomic pathway-based classifierPulseDIA

More Related Videos

A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions
09:00

A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions

Published on: April 18, 2025

652
Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer
12:23

Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer

Published on: August 2, 2018

12.2K

Related Experiment Videos

Last Updated: Jul 11, 2025

Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging
08:40

Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging

Published on: April 8, 2016

12.9K
A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions
09:00

A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions

Published on: April 18, 2025

652
Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer
12:23

Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer

Published on: August 2, 2018

12.2K

Area of Science:

  • Proteomics
  • Oncology
  • Immunology

Background:

  • Prostate cancer (PCa) is a leading global cancer in males.
  • Current risk stratification relies heavily on morphological examination.
  • Novel biomarkers are needed for improved PCa management.

Purpose of the Study:

  • To develop a novel pathway activity-based classifier for PCa risk stratification.
  • To identify distinct PCa subtypes based on proteomic profiles.
  • To correlate these subtypes with clinical outcomes and disease progression.

Main Methods:

  • Proteomic analysis of 667 PCa tumor samples using PulseDIA mass spectrometry.
  • Development of a 13-protein classifier across seven pathways.
  • Validation using independent transcriptome datasets.

Main Results:

  • Characterization of 9576 protein groups.
  • Identification of two PCa subtypes: PPS1 (enhanced innate immunity) and PPS2 (suppressed innate immunity).
  • PPS2 subtype significantly correlated with poorer biochemical recurrence/metastasis-free survival and enhanced cell proliferation.

Conclusions:

  • A novel pathway activity-based stratification scheme for PCa has been established.
  • The PPS1/PPS2 classification offers a new approach to PCa risk stratification.
  • This proteomic classifier has potential for guiding clinical decisions in prostate cancer management.